key: cord-0832334-jj02jtyf
authors: Zan, Jincan; Ma, Jun; Man, Qian; Liu, Xingzi; Yu, Donghe; Zhang, Yuemiao; Lv, Jicheng; Zhang, Hong
title: Safety evaluation of COVID-19 vaccine in patients with IgA nephropathy or IgA vasculitis nephritis
date: 2022-04-04
journal: Kidney Int Rep
DOI: 10.1016/j.ekir.2022.03.025
sha: ee4a3763207f3065aa2189d0f974575646deac06
doc_id: 832334
cord_uid: jj02jtyf

nan

To the Editor IgA nephropathy (IgAN) is the most commonly reported glomerulonephritis associated with COVID-19 vaccine. 1, 2 As an immunostimulant, safety is the principal concern of IgAN patients. Lim et al 3 reported that no patients experienced gross hematuria and few patients' serum creatinine rose slightly. However, the vaccine type restricted to mRNA vaccine and the sample size was small. Thus, the safety of COVID-19 vaccine in the population of IgAN still need to be fully explored.

We retrospectively investigated 965 IgAN or IgA vasculitis nephritis (IgAVN) patients and 46% (443/965) patients received at least one dose vaccination (Supplementary Figure S1 ). Of these, 76 patients vaccinated before kidney biopsy were excluded. (Table   1) .

Overall, COVID-19 vaccine was well tolerated in patients with IgAN, especially to those having relatively stable disease. Although GFR decline was observed in few patients, the change was temporary. But closely monitor of the kidney function after vaccination should be offered to intervene as early as possible. 

Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from ERA-IWG and EUVAS

COVID-19 Vaccination and Glomerulonephritis

COVID-19 Vaccination in Immunoglobulin A Nephropathy